ADDvise Group
ADDvise receives order worth EUR 2.6 million
ADDvise Group’s subsidiary MRC Systems has received an order from Rafarm, a leading pharmaceutical company based in Greece.
The order is worth approximately EUR 2.6 million. The order involves design, paneling, and installation of a cleanroom and associated accessories. Delivery of the order is scheduled to be completed during Q4 2025.
For further information, please contact:
Staffan Torstensson, CEO
+46 704 33 20 19
staffan.torstensson@addvisegroup.se
Important information
This information is information that ADDvise Group AB is required to disclose under the EU Market Abuse Regulation. The information was submitted for publication on December 19, 2024, at 07:55 CET.
About ADDvise Group
ADDvise is an international life science group. Operating a decentralised ownership model, we develop and acquire high quality companies within the business areas Lab and Healthcare. The Group comprises more than 20 companies and generates annual revenues of close to SEK 1.5 billion. ADDvise is listed on Nasdaq First North Premier Growth Market. Mangold Fondkommission AB, +46 8 503 015 50, CA@mangold.se, is the company's Certified Adviser. More information is available at www.addvisegroup.com.
| Datum | 2024-12-19, kl 07:55 |
| Källa | Cision |
Vill du synas här? Kontakta hej@allaaktier.se. Vår sajt har 100 000 sidvisningar och 15 000 unika besökare per månad. Vår discord har över 6000 medlemmar. Detta är aktiva sparare med ett stort aktieintresse. Behöver du nå ut till denna målgrupp så hör av dig!